At 0.5 to 2 mg, the dose is low enough that many people report feeling almost nothing for the first few days
For patients with type 2 diabetes or obesity, tirzepatide represents a well-studied, FDA-approved medication with demonstrated efficacy in clinical trials
GIP was one of many intestinal hormones scientists had uncovered by now
Fiber from whole grains, fruits, vegetables, and legumes helps maintain regularity and supports gut health
Eli Lilly's triple-hormone agonist targets GLP-1, GIP, and glucagon receptors simultaneously, creating a metabolic effect that researchers describe as unprecedented
The Triple Agonist Ceiling The data suggest that retatrutide may be approaching a clinical ceiling for weight loss via pharmacological means